Vaccination with TMEV Xho1-OVA8 enhances tumor antigen-restricted CD8+ T cell responses in the CNS, delays tumor progression, and extends survival in mice bearing GL261-Quad gliomas.
Two weeks post-GL261-Quad tumor introduction, mice were treated with control or recombinant picornavirus. (A,B) At five weeks, brain infiltrating lymphocytes were isolated, gated based on CD45 expression, and analyzed for CD8 and Kb:OVA257–264 tetramer positivity. (A) Representative FACS plots and (B) mean percent of Kb:OVA257–264+ cells per CD8+ cells demonstrate a significant increase in tumor antigen-restricted CD8+ T cells infiltrating the brain following intracranial (N = 9) or intraperitoneal (N = 10 mice) TMEV Xho1-OVA8 vaccine administration compared to TMEV-wt. Percent of Kb:OVA257–264+ / CD8+ calculated as Q2-2/(Q2-2+Q4-2)*100. (C,E) Mean bioluminescence intensity (p/sec) of GL261-Quad glioma-bearing mice treated with TMEV-wt or recombinant TMEV Xho1-OVA8 picornavirus. Mice receiving (C) intracranial (N = 15 mice) or (E) intraperitoneal (N = 13 mice) TMEV Xho1-OVA8 treatment displayed significantly delayed progression of established gliomas compared to TMEV-wt treated controls. (D,F) Delayed tumor progression is accompanied by a significant increase in survival for mice treated with TMEV Xho1-OVA8 via (D) intracranial or (F) intraperitoneal administration. Arrow denotes time of vaccine administration. (G) RT-PCR analysis of RNA isolated from brains of glioma-bearing mice demonstrates a significant reduction in transgene expression following treatment with TMEV Xho1-OVA8 compared to TMEV-wt treated controls. Error bars indicate SEM. * denotes p<0.05, ** denotes p<0.01, ***denotes p<0.001.